← All trials
NCT06213506
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2024
- Primary completion
- Apr 27, 2026
- Completion date
- Apr 27, 2026
- First posted
- Jan 19, 2024
- Last posted
- Jan 19, 2024
- Enrollment
- 516
- Arms / groups
- 22 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineOfficial
- Kwame Nkrumah University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.